Bayer is acquiring two investigational molecular imaging agents from Attralus for the diagnosis of cardiac amyloidosis. AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) are two tracers currently in clinical development. Potentially, they may address the urgent need to accurately diagnose a disease that affects approximately 400,000 people globally. “With this strategic acquisition and the integration of novel molecular tracers into our development portfolio, we are adva...